OPZELURA was studied in two clinical trials, totaling more than 1200 people with mild to moderate eczema for 8 weeks and was proven to help clear the visible signs of eczema and significantly reduce itch. Studies of OPZELURA included people with a range of skin tones ages 12 and older. Individual results may vary.
In a clinical study
More than half of patients achieved
AFTER 8 WEEKS
54% of those using OPZELURA 1.5% cream achieved clear or almost clear skin at Week 8 compared with 15% of those not using OPZELURA.
More than half of patients
52% of those using OPZELURA 1.5% cream achieved significant itch
reduction at Week 8 compared to 15% of those not using OPZELURA.
Similar results were seen in another clinical study.
OPZELURA was applied twice daily for 8 weeks and was applied by patients on areas of the skin where they had eczema, including sensitive ones such as the face. OPZELURA is only for use on affected areas that cover up to 20% of the body, as directed by your healthcare provider. OPZELURA is for use on the skin only. Do not use in your eyes, mouth or vagina.
Stop using OPZELURA when signs and symptoms (e.g., itch, rash, and redness) of eczema resolve. Talk to your healthcare provider if you don't see an improvement within 8 weeks.
The following photos are from an actual patient who participated in the clinical study and show results from before the study and the results after 8 weeks of treatment with OPZELURA. Individual results may vary. OPZELURA was not studied in patients with severe eczema.
OPZELURA was studied in 2 double-blind, vehicle-controlled clinical trials. This means that participants received either OPZELURA or just the vehicle—a cream with no active ingredients. Participants were not told which they received. More than 1200 people with mild to moderate eczema participated in these trials for 8 weeks, with 20% of participants ranging in age from 12-17 years old.
Who participated in the trials?
Gender: 62% female, 38% male
Percentage of body area affected by eczema: 3% to 20%. The average affected area was 9.8%.
- 70% Caucasian
- 23% Black/African American
- 4% Asian
Severity*: Participants had an eczema severity of
2 (mild) or 3 (moderate) on a scale of 0 to 4, (where 0 represented no eczema and 4 represented severe eczema)
*People with severe eczema were not included in the trial.
Were there any side effects?
The most common side effects of OPZELURA include: pain or swelling in your nose or throat (nasopharyngitis), diarrhea, bronchitis, ear infection, increase in a type of white blood cell (eosinophil) count, hives, inflamed hair pores (folliculitis), swelling of the tonsils (tonsillitis), and runny nose (rhinorrhea).